The content on this site is intended for healthcare professionals only
At a press conference at ASCO 2014, Dr Ribas talks about his work which looks at the efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
Read the article for more.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
Gynaecological cancer: New targets and immunotherapy developments
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
The current status of multiple myeloma diagnosis and treatment
